As TET1 mutations were most common in colorectal cancer, bladder cancer, and melanoma patients (Fig. 3C), we subsequently evaluated the relationship between TET1 mutation and overall survival in these cancers specifically. Here, TET1 is linked to urinary bladder cancer.